Literature DB >> 35549445

Practice Management Strategies for Imaging Facilities Facing an Acute Iodinated Contrast Media Shortage.

Joseph J Cavallo1, Jay K Pahade1.   

Abstract

An unanticipated but severe shortage in iodinated contrast media (ICM) is currently affecting imaging practices across the globe and is expected to persist through at least the end of June 2022. This supply shock may lead health care systems to experience an acute imaging crisis, given that many affected facilities have contrast agent supplies that are anticipated to last only a week or two under normal operating conditions. To maximize the opportunity to continue to provide optimal care for patients with emergent or life-threatening imaging indications and thereby minimize the overall impact on patient care, practice leaders will need to quickly assess their contrast material inventories, prioritize examination indications, and reduce their expected short-term usage of ICM. This Clinical Perspective reviews ICM conservation techniques that the Yale School of Medicine has deployed or is considering deploying, depending on the severity and length of the supply shortage.

Entities:  

Keywords:  CECT; contrast media; management

Mesh:

Substances:

Year:  2022        PMID: 35549445     DOI: 10.2214/AJR.22.27969

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   6.582


  2 in total

1.  What the Baby Formula and Medical Contrast Material Shortages Have in Common: Insights and Recommendations for Managing the Iodinated Contrast Media Shortage.

Authors:  Lakshmi Ananthakrishnan; Fernando U Kay; Eric A Zeikus; Eugene S Chu; Joseph Chang; John D Barr; Neil M Rofsky; Suhny Abbara
Journal:  Radiol Cardiothorac Imaging       Date:  2022-05-25

2.  Navigating Supply Chain Disruptions of Iodinated Contrast Agent for Neuroimaging and How Business Intelligence Can Help the Decision Process.

Authors:  R Bammer; S A Amukotuwa
Journal:  AJNR Am J Neuroradiol       Date:  2022-06-01       Impact factor: 4.966

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.